Profile data is unavailable for this security.
About the company
United Therapeutics Corporation is a pharmaceutical company. It markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin) for treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder.
- Revenue in USD (TTM)2.76bn
- Net income in USD1.11bn
- Incorporated1996
- Employees1.17k
- LocationUnited Therapeutics Corp1000 SPRING STSILVER SPRING 20910United StatesUSA
- Phone+1 (301) 608-9292
- Fax+1 (301) 608-9291
- Websitehttps://www.unither.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revolution Medicines Inc | 742.00k | -567.06m | 9.55bn | 490.00 | -- | 6.08 | -- | 12,872.64 | -3.59 | -3.59 | 0.0047 | 9.34 | 0.0005 | -- | 4.80 | 1,962.96 | -41.28 | -29.76 | -44.46 | -32.59 | -- | -- | -76,423.31 | -606.93 | -- | -- | 0.00 | -- | -67.27 | -10.50 | -75.46 | -- | 38.82 | -- |
| Exact Sciences Corp | 2.69bn | -214.04m | 9.82bn | 6.50k | -- | 3.06 | 5,387.82 | 3.65 | -1.17 | -1.17 | 14.70 | 17.35 | 0.4089 | 5.40 | 11.60 | 414,204.30 | -3.25 | -9.71 | -3.58 | -10.60 | 72.96 | 74.10 | -7.95 | -28.21 | 1.93 | -- | 0.4459 | -- | 19.93 | 40.63 | 67.26 | -- | -3.71 | -- |
| Charles River Lbrtrs ntrntl Inc | 4.06bn | 413.08m | 9.93bn | 20.00k | 24.24 | 2.63 | 12.93 | 2.45 | 8.01 | 8.01 | 78.63 | 73.97 | 0.5203 | 8.27 | 5.23 | 203,045.80 | 5.48 | 6.46 | 6.33 | 7.62 | 35.93 | 36.99 | 10.54 | 11.58 | 1.14 | 4.96 | 0.3784 | 0.00 | 3.86 | 12.75 | -2.39 | 16.69 | 17.86 | -- |
| Exelixis Inc | 2.08bn | 466.92m | 9.95bn | 1.31k | 22.20 | 4.37 | 20.11 | 4.78 | 1.57 | 1.57 | 6.92 | 7.96 | 0.7012 | 3.39 | 8.04 | 1,589,006.00 | 15.73 | 8.86 | 18.08 | 9.91 | 96.25 | 96.30 | 22.43 | 15.43 | 3.88 | -- | 0.00 | 0.00 | 13.60 | 16.47 | 13.98 | -21.34 | 3.98 | -- |
| Sarepta Therapeutics Inc | 1.64bn | 121.85m | 10.55bn | 1.31k | 90.87 | 8.64 | 65.77 | 6.43 | 1.22 | 1.22 | 16.30 | 12.79 | 0.489 | 0.5703 | 4.35 | 1,248,362.00 | 3.63 | -21.63 | 4.38 | -25.75 | 85.92 | 86.65 | 7.43 | -77.05 | 3.03 | -- | 0.5013 | -- | 33.26 | 32.80 | 23.81 | -- | 6.30 | -- |
| Medpace Holdings Inc | 2.07bn | 365.57m | 10.62bn | 5.90k | 29.93 | 12.03 | 26.94 | 5.13 | 11.42 | 11.42 | 64.70 | 28.42 | 1.16 | -- | 6.85 | 350,994.30 | 20.48 | 13.94 | 43.51 | 23.18 | 29.69 | 28.84 | 17.66 | 15.23 | -- | -- | 0.00 | -- | 29.17 | 21.76 | 15.26 | 31.17 | 17.99 | -- |
| Vaxcyte Inc | 0.00 | -507.65m | 11.02bn | 254.00 | -- | 3.22 | -- | -- | -4.55 | -4.55 | 0.00 | 27.47 | 0.00 | -- | -- | 0.00 | -20.08 | -34.22 | -20.95 | -37.21 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -80.00 | -- | 107.28 | -- |
| BIO-TECHNE Corp | 1.17bn | 150.68m | 11.29bn | 3.10k | 75.57 | 5.28 | 43.09 | 9.64 | 0.9402 | 0.9402 | 7.29 | 13.46 | 0.4267 | 2.15 | 5.47 | 377,930.00 | 5.49 | 9.42 | 5.77 | 10.04 | 65.93 | 67.29 | 12.86 | 21.41 | 3.26 | 18.07 | 0.123 | 22.79 | 1.97 | 10.17 | -41.07 | 11.86 | 19.87 | 0.00 |
| Neurocrine Biosciences, Inc. | 2.24bn | 385.90m | 12.66bn | 1.70k | 33.47 | 4.65 | 30.75 | 5.64 | 3.73 | 3.73 | 21.67 | 26.87 | 0.7027 | 0.8901 | 4.99 | 1,602,000.00 | 12.09 | 9.77 | 14.67 | 12.19 | 98.52 | 98.51 | 17.21 | 14.79 | 4.26 | 10.28 | 0.00 | -- | 26.76 | 33.13 | 61.62 | 63.90 | 2.67 | -- |
| Insmed Inc | 342.96m | -864.29m | 13.20bn | 912.00 | -- | 27.31 | -- | 38.50 | -5.56 | -5.56 | 2.21 | 2.70 | 0.2031 | 0.8848 | 8.81 | 376,050.40 | -51.17 | -40.96 | -59.16 | -46.88 | 77.25 | 77.99 | -252.01 | -212.92 | 5.99 | -18.41 | 0.6702 | -- | 24.39 | 98.78 | -55.66 | -- | -2.15 | -- |
| Summit Therapeutics Inc | 0.00 | -196.68m | 13.58bn | 105.00 | -- | 31.00 | -- | -- | -0.2768 | -0.2768 | 0.00 | 0.5941 | 0.00 | -- | -- | 0.00 | -54.53 | -77.32 | -71.71 | -86.35 | -- | -- | -- | -20,989.46 | -- | -- | 0.053 | -- | -100.00 | -- | -680.54 | -- | -4.84 | -- |
| Moderna Inc | 5.08bn | -2.22bn | 14.72bn | 5.60k | -- | 1.23 | -- | 2.90 | -5.81 | -5.81 | 13.14 | 30.98 | 0.2883 | 2.44 | 2.96 | 907,321.40 | -12.62 | 20.95 | -15.52 | 29.51 | 78.43 | -- | -43.77 | 32.10 | 4.20 | -- | 0.0521 | 0.00 | -64.45 | 119.28 | -156.37 | -- | 46.22 | -- |
| United Therapeutics Corporation | 2.76bn | 1.11bn | 16.40bn | 1.17k | 16.15 | 2.69 | 13.93 | 5.95 | 22.75 | 22.75 | 56.36 | 136.74 | 0.3897 | 2.43 | 9.18 | 2,359,760.00 | 15.71 | 10.38 | 17.73 | 11.27 | 88.94 | 91.47 | 40.31 | 29.25 | 4.41 | -- | 0.0615 | 0.00 | 20.20 | 7.41 | 35.40 | 10.89 | 4.55 | -- |
| ICON PLC | 8.31bn | 747.89m | 17.57bn | 42.25k | 23.65 | 1.80 | 13.62 | 2.11 | 8.99 | 8.99 | 99.87 | 118.39 | 0.4852 | -- | 2.99 | 202,112.50 | 4.37 | 3.93 | 5.24 | 4.80 | 29.65 | 28.91 | 9.00 | 7.37 | -- | 4.41 | 0.2599 | -- | 4.89 | 25.62 | 21.18 | 13.67 | 23.79 | -- |
Data as of Nov 21 2024. Currency figures normalised to United Therapeutics Corp's reporting currency: US Dollar USD
50.55%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 30 Sep 2024 | 4.37m | 9.82% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 4.35m | 9.77% |
| Avoro Capital Advisor LLCas of 30 Sep 2024 | 2.86m | 6.43% |
| Wellington Management Co. LLPas of 30 Sep 2024 | 2.61m | 5.87% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 2.24m | 5.03% |
| Renaissance Technologies LLCas of 30 Sep 2024 | 2.16m | 4.85% |
| Geode Capital Management LLCas of 30 Sep 2024 | 1.09m | 2.46% |
| LSV Asset Managementas of 30 Sep 2024 | 969.47k | 2.18% |
| AQR Capital Management LLCas of 30 Sep 2024 | 967.73k | 2.18% |
| Fidelity Management & Research Co. LLCas of 30 Sep 2024 | 878.21k | 1.97% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
